Global Acute Respiratory Distress Syndrome Devices Market Report 2023: North America Remains the Global Leader - Growth Trends, Key Players, Competitive Strategies and Forecasts to 2031
02 mars 2023 07h08 HE
|
Research and Markets
Dublin, March 02, 2023 (GLOBE NEWSWIRE) -- The "Global Acute Respiratory Distress Syndrome Devices Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players,...
Adamis Pharmaceuticals and DMK Pharmaceuticals Announce Agreement and Plan of Merger
27 févr. 2023 16h05 HE
|
Adamis Pharmaceuticals Corporation
Combined company will have commercial products and a library of development candidates, two of which are clinical stageWill be under the leadership of DMK CEO, Dr. Ebrahim (Eboo) Versi MD, PhDLead...
Nasdaq Grants Adamis Pharmaceuticals’ Request for Extension to Comply with Continued Listing Requirements
22 févr. 2023 16h01 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing...
Adamis Pharmaceuticals Schedules Third Quarter 2022 Financial Results Conference Call and Corporate Update
07 nov. 2022 16h05 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Veru Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022
24 oct. 2022 08h30 HE
|
Veru Inc.
MIAMI, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for...
Adamis Announces Review of Strategic Alternatives
03 oct. 2022 16h30 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in...
Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders
12 août 2022 17h00 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its 2022 Annual Meeting of Stockholders (“Annual Meeting”) was convened, as...
Adamis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
10 août 2022 16h02 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing...
Adamis Pharmaceuticals Schedules Second Quarter 2022 Financial Results Conference Call and Corporate Update
08 août 2022 07h30 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Global Cystic Fibrosis Market Report 2022-2030 - Expanding Therapeutic Options is Expected to Drive Market Growth
03 août 2022 08h03 HE
|
Research and Markets
Dublin, Aug. 03, 2022 (GLOBE NEWSWIRE) -- The "Cystic Fibrosis Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts,...